Table 2.
Study | CT-STAT40 |
ACRIN46 |
ROMICAT II51 |
|||
---|---|---|---|---|---|---|
Population (n) | 699 | 1370 | 1000 | |||
Mean age (years) | 50 | 49 | 54 | |||
Women (%) | 54 | 53 | 47 | |||
TIMI risk score | 0–4 | 0–2 | N/A | |||
MI during index hospitalization (%) | 0.9 | 0.9 | 2.3 | |||
Control group | Stress myocardial perfusion imaging | Standard of care | Standard of care | |||
Randomization | 1:1 | 2:1 | 1:1 | |||
Number of centres | 16 | 5 | 9 | |||
Conventional Tn assays and thresholds used in the study | Tn I, Bayer, thresholds not reported | Not reported | Tn T, Roche: 0.03 ng/mL Tn I, Alere: 0.40 ng/mL Tn I, Beckman: 0.07/0.04 ng/mL |
|||
Coronary CTA | Controls | Coronary CTA | Controls | Coronary CTA | Controls | |
ACS during index hospitalization (%) | 1.2 | 2.7 | 4 | 2 | 9 | 6 |
MACE during follow-up (%) | 0.8 | 0.4 | 3 | 1 | 0.4 | 1.2 |
Time to diagnosis (h) | 2.9a | 6.2a | – | – | – | – |
Length of stay (h) | – | – | 18.0a | 24.8a | 23.2a | 30.8a |
Direct ED discharges (%) | – | – | 50a | 23a | 47a | 12a |
Invasive coronary angiography (%) | 7 | 6 | 5 | 4 | 11 | 7 |
Coronary revascularization (%) | 4 | 2 | 3 | 1 | 7 | 4 |
ED cost ($) | 2137 | 3458 | – | – | 2101 | 2566 |
Radiation dose (mSv) | 12 | 13 | – | – | 14a | 5a |
aSignificant difference between coronary CTA and control groups (P < 0.05).